Pipeline: Presbyopia, night vision disturbance up next for Vyluma

Presbyopia and night vision disturbance will follow myopia as a clinical focus for Vyluma. Navneet Puri, PhD, the company’s founder, chairman, and CEO, shares what is next.

Related Videos
Alexis Malkin, OD, FAAO, highlights her Vision Expo West 2022 presentation titled, "Expand your practice: how to integrate low vision into everyday patient care and improve outcomes."
 Valerie M. Kattouf, OD, associate professor of optometry and chief of the Dr. Robert and Lena Lewenson Center for Pediatric and Binocular Vision, Illinois College of Optometry, speaks with Optometry Times®' Alex Delaney-Gesing on key highlights and takeaways from her 2022 Vision Expo West presentation titled "Myopia Control."
Ashley Tucker, OD, FAAO, FSLS, Dipl ABO, shares highlights from her discussion titled, "Myopia management: past, present, and future," presented during this year's 115th annual SCOPA meeting.
Kelly Voltz, OD, FAAO, FSLS, on highlights from her presentation "Ortho-K" during the 2022 SECO meeting.
© 2023 MJH Life Sciences

All rights reserved.